UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Obesity in early onset breast cancer in African American patients

The breast journal, 2021-07, Vol.27 (7), p.603-607

2021

Volltextzugriff (PDF)

Patient preferences regarding incidental genomic findings discovered during tumor profiling

Cancer, 2016-05, Vol.122 (10), p.1588-1597

2016

Volltextzugriff (PDF)

Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

Cancer, 2015-08, Vol.121 (15), p.2544-2552

2015

Volltextzugriff (PDF)

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Clinical cancer research, 2016-07, Vol.22 (13), p.3249-3259

2016

Volltextzugriff (PDF)

New Strategies in Breast Cancer: Immunotherapy

Clinical cancer research, 2016-05, Vol.22 (9), p.2105-2110

2016

Volltextzugriff (PDF)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

NPJ precision oncology, 2023-02, Vol.7 (1), p.18-18, Article 18

2023

Volltextzugriff (PDF)

Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer

NPJ breast cancer, 2021-06, Vol.7 (1), p.72-8, Article 72

2021

Volltextzugriff (PDF)

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

Cancer, 2015-06, Vol.121 (11), p.1817-1826

2015

Volltextzugriff (PDF)

Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy

Breast cancer research and treatment, 2019-07, Vol.176 (2), p.261-270

2019

Volltextzugriff (PDF)

Coverage for evidence-based cancer survivorship care services

Supportive care in cancer, 2024-03, Vol.32 (3), p.165-165, Article 165

2024

Volltextzugriff (PDF)

Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors

Breast cancer research and treatment, 2020-06, Vol.181 (3), p.679-689

2020

Volltextzugriff (PDF)

Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA

European journal of cancer (1990), 2019-01, Vol.106, p.133-143

2019

Volltextzugriff (PDF)

The cost of breast cancer screening in the Medicare population

JAMA internal medicine, 2013-02, Vol.173 (3), p.220

2013

Volltextzugriff (PDF)

Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study

Journal of the National Comprehensive Cancer Network, 2017-03, Vol.15 (3), p.346-354

2017

Volltextzugriff (PDF)

Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy

Breast cancer research and treatment, 2015-02, Vol.150 (1), p.157-167

2015

Volltextzugriff (PDF)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

BMC cancer, 2014-05, Vol.14 (1), p.326-326, Article 326

2014

Volltextzugriff (PDF)

prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer

Breast cancer research and treatment, 2009-04, Vol.114 (3), p.513-515

2009

Volltextzugriff (PDF)

Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

International journal of gynecological cancer, 2014-03, Vol.24 (3), p.528-533

2014

Volltextzugriff (PDF)

Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients

Current opinion in ophthalmology, 2009-07, Vol.20 (4), p.308-317

2009

Volltextzugriff (PDF)

Anthracycline-induced cardiotoxicity: risk assessment and management

Oncology (Williston Park, N.Y.), 2009-03, Vol.23 (3), p.239, 244, 252

2009

Volltextzugriff (PDF)

DTCs/CTCs in breast cancer: five decades later

Recent results in cancer research, 2012, Vol.195, p.217

2012

Volltextzugriff (PDF)

Cancer therapy related cardiotoxicity

Current cardiology reviews, 2011-11, Vol.7 (4), p.213-213

2011

Volltextzugriff (PDF)

Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008–2011

Journal of geriatric oncology, 2016-01, Vol.7 (1), p.15-23

2016

Volltextzugriff (PDF)

Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer

Breast cancer research and treatment, 2007-09, Vol.104 (3), p.341-349

2007

Volltextzugriff (PDF)

Meta-analysis of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy versus endocrine therapy alone on progression-free survival (PFS) and overall survival (OS) for metastatic breast cancer (MBC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1060-1060

2020

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(73)
Buchkapitel
(1)

Sprache

Englisch
(74)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Obesity in early onset breast cancer in African American patients

Patient preferences regarding incidental genomic findings discovered during tumor profiling

Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

New Strategies in Breast Cancer: Immunotherapy

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy

Coverage for evidence-based cancer survivorship care services

Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors

Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA

The cost of breast cancer screening in the Medicare population

Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study

Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer

Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients

Anthracycline-induced cardiotoxicity: risk assessment and management

DTCs/CTCs in breast cancer: five decades later

Cancer therapy related cardiotoxicity

Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008–2011

Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer

Meta-analysis of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy versus endocrine therapy alone on progression-free survival (PFS) and overall survival (OS) for metastatic breast cancer (MBC)

Suchergebnisse filtern